<DOC>
	<DOCNO>NCT00949455</DOCNO>
	<brief_summary>RATIONALE : Lapatinib ditosylate may stop growth tumor cell block enzymes need cell growth . It yet know whether lapatinib ditosylate effective placebo kill tumor cell . PURPOSE : This randomized phase II/III trial study well lapatinib ditosylate work compare placebo treat patient stage IV bladder cancer .</brief_summary>
	<brief_title>A Double Blind Randomised Study Lapatinib Placebo Metastatic TCC Urothelium</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient HER1- and/or HER2-overexpressing stage IV bladder cancer randomize maintenance therapy lapatinib ditosylate placebo follow first-line chemotherapy . Secondary - Compare overall survival patient group . - Evaluate safety tolerability regimens patient . - Assess compare quality life patient group . OUTLINE : This multicenter study . Patients stratify accord ECOG performance status response first line chemotherapy ( complete partial response v stable disease ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral lapatinib ditosylate daily absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo daily absence disease progression unacceptable toxicity . Patients undergo quality life assessment EORTC QLQ-C30 baseline every 4 week study treatment . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder Stage IV disease Metastatic locally advance disease HER1 and/or HER2positive disease , define follow criterion : 2+ 3+ intensity IHC Able commence study treatment within 10 week complete chemotherapy Must achieve objective response stable disease follow 48 course firstline chemotherapy No progression firstline chemotherapy metastatic disease Any widely accept chemotherapy regimen bladder cancer allow Patients receive cisplatin eligible PATIENT CHARACTERISTICS : ECOG performance status 03 ANC ≥ 1.0 x 10^9/L Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 75 x 10^9/L ALT/AST &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Serum creatinine ≤ 3.0 ULN AND/OR creatinine clearance ≥ 30 mL/min LVEF ≥ 50 % ( assessed quantitative echocardiogram MUGA ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No current active hepatic biliary disease , except follow : Gilbert 's syndrome Asymptomatic gallstone Liver metastases Stable chronic liver disease per investigator assessment No known hypersensitivity study medication No history prior concurrent neoplasm , except : Any non lifethreatening tumour curatively treat . Prostate cancer isolate prostate gland No significant cardiac disease , include follow : Angina pectoris Severe cardiac arrhythmia require medication Severe conduction abnormality Clinically significant valvular disease Cardiomegaly Prior myocardial infarction Ventricular hypertrophy Congestive heart failure Poorly uncontrolled hypertension ( rest diastolic blood pressure &gt; 115 mm Hg ) Other cardiomyopathy No serious intercurrent medical psychiatric illness No serious active infection PRIOR CONCURRENT THERAPY : See Disease Characteristics No 1 line prior chemotherapy metastatic locally advanced disease ( neoadjuvant/adjuvant chemotherapy allow ) No 10 week since firstline chemotherapy No prior lapatinib ditosylate No prior radiotherapy indicator lesion ( ) ( newly arise lesion previously irradiate area allow ) At least 14 day since prior concurrent CYP3A4 inducer , include limited , follow : Antibiotics ( rifamycin class agent [ e.g. , rifampicin , rifabutin , rifapentine ] ) Anticonvulsants ( phenytoin , carbamazepine , barbiturates [ e.g. , phenobarbital ] ) Oral glucocorticoid ( cortisone [ &gt; 50 mg ] , hydrocortisone [ &gt; 40 mg ] , prednisone [ &gt; 10 mg ] , methylprednisolone [ &gt; 8 mg ] , dexamethasone [ &gt; 2 mg² ] ) St. John 's wort modafinil At least 7 day since prior concurrent CYP3A4 inhibitor , include limited , follow : Antibiotics ( clarithromycin , erythromycin , troleandomycin ) Antifungals ( itraconazole , ketoconazole , fluconazole [ &gt; 150 mg daily ] , voriconazole ) Antiretrovirals/protease inhibitor ( delavirdine , nelfinavir , amprenavir , ritonavir , indinavir , saquinavir , lopinavir ) Calcium channel blocker ( verapamil , diltiazem ) Antidepressants ( nefazodone , fluvoxamine ) Gastrointestinal agent ( cimetidine , aprepitant ) Grapefruit , grapefruit juice At least 6 month since prior concurrent amiodarone No concurrent radical curative therapy ( radiotherapy surgery ) end firstline treatment ( palliative radiotherapy allow ) No concurrent experimental investigational drug No concurrent anticancer treatment , include cytotoxic specific immune therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>